Canaccord Genuity Maintains Hold on Zimmer Biomet Holdings, Lowers Price Target to $120
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity has maintained a Hold rating on Zimmer Biomet Holdings but lowered the price target from $130 to $120, indicating a cautious outlook.
August 20, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Canaccord Genuity has maintained a Hold rating on Zimmer Biomet Holdings but lowered the price target from $130 to $120, suggesting a cautious outlook on the stock.
The Hold rating suggests that the analyst does not see significant upside potential in the stock, and the lowered price target indicates a more conservative valuation. This could lead to a negative short-term impact on the stock price as investors may adjust their expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100